RANKL/OPG in Breast Cancer — Extending Its Territory to BRCA Mutation Carriers

Similar Items

• Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
  od: Zaman, Tasnim, i dr.
  Izdano: (2019)
• Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
  od: Rebbeck, Timothy R, i dr.
  Izdano: (2008)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  od: Martin Widschwendter, i dr.
  Izdano: (2015-10-01)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  od: Widschwendter, Martin, i dr.
  Izdano: (2015)
• Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer?
  od: Narod, Steven A.
  Izdano: (2019)